
MiNK Therapeutics (INKT) Stock Forecast & Price Target
MiNK Therapeutics (INKT) Analyst Ratings
Bulls say
MiNK Therapeutics Inc has experienced a significant increase in its stock price, rising over 400% recently compared to a mere 2% increase in the Nasdaq Biotechnology Index, reflecting strong market enthusiasm. The company’s innovative approach to iNKT cell therapies, characterized by scalable and cost-effective manufacturing capabilities and dual mechanisms of action, positions it favorably within the biopharmaceutical landscape. Furthermore, ongoing and upcoming clinical trials—including the agenT-797 Phase 2 gastric trial—are anticipated to attract additional investment and validate the therapeutic potential of its product pipeline.
Bears say
MiNK Therapeutics Inc. faces significant risks that could negatively impact its stock, including the potential emergence of safety signals in ongoing clinical or preclinical programs, which could hinder its therapeutic advancement. The company also risks lower-than-expected efficacy from its clinical trials, greater competition within the market, and potential regulatory challenges affecting its assets. Additionally, there are concerns regarding financing needs amounting to approximately $55 million through 2038, a limited cash runway extending only into mid-2025, and the risk of de-listing if share prices fall below $1.
This aggregate rating is based on analysts' research of MiNK Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
MiNK Therapeutics (INKT) Analyst Forecast & Price Prediction
Start investing in MiNK Therapeutics (INKT)
Order type
Buy in
Order amount
Est. shares
0 shares